TFF Pharmaceuticals, Inc. (TFFP) — Financial statements
Income statement, balance sheet, and cash flow for TFF Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.73 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.50↑29.4% | 0.39↑248.3% | 0.11 | 0.00 | 0.00 | |
| Gross Profit | 0.23↑159.6% | -0.39↓248.3% | -0.11 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 12↓37.5% | 18↓13.2% | 21↑99.4% | 11↑21.1% | 9 | |
| General & Administrative Expenses | 11↓23.4% | 14↑30.5% | 11↑32.0% | 8↑153.1% | 3 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 11↓23.4% | 14↑30.5% | 11↑32.0% | 8↑153.1% | 3 | |
| Other Expenses | 0.00↑100.0% | -0.50↓462.4% | -0.09 | 0.00 | 0.00 | |
| Operating Expenses | 22↓30.4% | 32↑0.0% | 32↑70.0% | 19↑55.9% | 12 | |
| Total Costs & Expenses | 23↓28.8% | 32↑0.0% | 32↑70.0% | 19↑55.9% | 12 | |
| Operating Results | ||||||
| Operating Income | -22↑31.1% | -32↓0.0% | -32↓70.0% | -19↓55.9% | -12 | |
| Depreciation & Amortization | 0.50↑29.4% | 0.39↑248.3% | 0.11↓46.0% | 0.21↑20.0% | 0.17 | |
| EBITDA | -21↑34.0% | -31↓1.6% | -31↓65.4% | -19↓55.9% | -12 | |
| EBIT | -21↑33.1% | -32↓2.4% | -31↓67.2% | -19↓56.4% | -12 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓100.0% | 0.03↓47.8% | 0.05↓59.5% | 0.13↑7.7% | 0.12 | |
| Interest Income | 0.00↓100.0% | 0.03↓47.8% | 0.05↓59.5% | 0.13↑7.7% | 0.12 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -0.65↓2337.7% | -0.03↑96.4% | -0.75↓491.7% | -0.13↓7.7% | -0.12 | |
| Other Income / Expenses | 0.65↑2337.3% | 0.03↓96.4% | 0.75↑491.7% | 0.13↑7.7% | 0.12 | |
| Income Before Tax | -21↑33.1% | -32↓2.4% | -31↓67.2% | -19↓56.4% | -12 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -21↑33.1% | -32↓2.4% | -31↓67.2% | -19↓56.4% | -12 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -21↑33.1% | -32↓2.5% | -31↓68.0% | -18↓56.9% | -12 | |
| Bottom-Line Net Income | -21↑33.1% | -32↓2.4% | -31↓67.2% | -19↑49.4% | -37 | |
| EPS (Basic) | -11.85↑55.3% | -26.49↑15.1% | -31.21↓38.3% | -22.57↑47.0% | -42.55 | |
| EPS (Diluted) | -11.85↑55.3% | -26.49↑15.1% | -31.21↓38.3% | -22.57↑47.0% | -42.55 | |
| Weighted Average Shares | 2↑49.5% | 1↑20.8% | 0.99↑21.5% | 0.82↑195.8% | 0.28 | |
| Weighted Average Diluted Shares | 2↑49.5% | 1↑20.8% | 0.99↑21.5% | 0.82↑195.8% | 0.28 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.